Teva Version of Amgen Drug Delayed by FDA

U.S. health regulators on Thursday delayed approval of Teva Pharmaceutical Industries Ltd’s biotechnology medicine to boost white blood cells that is similar to Amgen Inc’s big-selling Neupogen.
XE